Shots: Mitokinin to receive an up front and will continue to develop its PINK1 activator program through completion of IND enabling studies for its lead compound. If IND-enabling studies are […]readmore
Tags : Acquire
Shots: Hologic to acquire Diagenode for ~$159M. The transaction will expand and diversifies Hologic’s diagnostic business across test menu, customer segments and geography The acquisition will strengthen Hologic’s molecular diagnostics […]readmore
Shots: Roivant to acquire Silicon for $450M in Roivant’s equity with additional potential regulatory and commercial milestones. The acquisition will strengthen Roivant’s AI capabilities for drug discovery The acquisition of […]readmore
Shots: Merck to acquire all outstanding shares of Pandion for $60/share in cash, representing the equity value of ~$1.85B. The transaction is expected to close in H1’21 The acquisition will […]readmore
Shots: GSK to receive $350M at closing, along with ~$150M as milestones. The transaction is expected to close in H2’21 The transaction will allow GSK to prioritize and simplify its […]readmore
Shots: Jazz to acquire GW Pharmaceuticals for $220/ GW ADS, out of which $200 in cash and $20 in Jazz ordinary shares, making a total deal value $7.2B with a […]readmore
Shots: Horizon to acquire Viela Bio for $53/ share, representing an equity value of $3.05B with a 53% premium over a closing price to Viela’s on Jan 29, 2020. Additionally, […]readmore
Shots: Boston Scientific to acquire Preventice for ~$1.2B including $925M as up front, up to an additional $300M as commercial milestones. However, Boston Scientific has built up a 22% stake […]readmore
Shots: Cardiva to receive $475M up front and up to an additional ~$35M in contingent consideration based on sales growth. The transaction is expected to be completed in Q1’21 The […]readmore
Shots: Thermo Fisher acquires Mesa Biotech for $450M in cash. Mesa Biotech will receive an additional ~$100M in cash on the completion of milestones while the transaction is expected to […]readmore